Charles River Laboratories stock at USD 294.59 on September 28, 2026
Published on 09/28/2026 at 22:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Charles River Laboratories International, Inc. shares were quoted at USD 294.59 at 8:00:02 PM UTC on September 28, 2026, up USD 1.75, or 0.60 percent, from the prior close.
Trading session
The stock trades on the New York Stock Exchange under the ticker CRL. The quoted price and daily change are presented separately from the company developments announced earlier in September.
Investor Day guidance
At its September 24, 2026, Investor Day, Charles River Laboratories outlined its Pathway to Purpose strategy and reaffirmed its 2026 financial guidance. The company said 2026 organic revenue growth and non-GAAP earnings per share are expected at the upper ends of prior ranges. Its stated guidance includes organic revenue growth at the upper end of 0.00 percent to 1.00 percent and non-GAAP EPS at the upper end of USD 11.15 to USD 11.45.
2030 targets
The company also introduced long-term targets through 2030, including a non-GAAP operating margin of 21.00 percent to 21.30 percent. Charles River said it expects bioanalysis revenue to reach approximately USD 450.00 million in 2030 and expects its Create the Future program to generate more than USD 300.00 million in cumulative savings from 2027 through 2030. The company stated that the 2030 financial targets do not include the impact of future acquisitions or divestitures.
